Mylan narrows full-year revenue, profit forecast

Thu Aug 7, 2014 6:48am EDT

Aug 7 (Reuters) - Generic drug maker Mylan Inc narrowed its full-year revenue and earnings forecast, citing delays in U.S. Food and Drug Administration approval of key products.

The company narrowed its revenue forecast range to $7.8 billion-$8 billion from $7.8 billion-$8.2 billion.

Mylan also narrowed its full-year earnings forecast range to $3.25-$3.45 per share from $3.25-$3.60. (Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.